Other News To Note
Wednesday, June 8, 2011
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Bayer HealthCare, of Leverkusen, Germany, announced that Bayer HealthCare submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion, diabetic macular edema and myopic choroidal neovascularization.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.